Navigation Links
Bioheart Reports Significant Improvements in Heart Failure Patients from Center of Excellence Program
Date:8/26/2010

em. Two of the patients have completed the 3-month follow-up testing. A significant improvement was seen in both the 6-minute walk as well as the left ventricular ejection fraction (LVEF). The first patient improved his walking distance from 315 to 420 meters and LVEF from 32% to 38%. The second patient improved his walking distance from 450 to 492 meters and LVEF from 40% to 55%.

Mike Tomas, Bioheart's President and Chief Executive Officer added, "We are extremely excited about the Center of Excellence established in Mexico and the preliminary results are very promising. We look forward to providing novel therapies and regenerative medicine to additional heart failure patients whose options are currently limited."

About the TGI 1200 Cell Isolation System

The CE-marked TGI 1200 Cell Isolation System is a fully automated and easy-to-use system, which processes liposuctioned fat tissue and delivers isolated regenerative cells in about an hour. The instrument allows for point-of-care recovery of an average of 30 to 40 million regenerative cells per 60cc of a patient's processed fat. These cells can then be used at the site of injury or disease.

About Bioheart, Inc.

Bioheart is committed to maintaining our leading position within the cardiovascular sector of the cell technology industry delivering cell therapies, intelligent devices and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. We work to prevent the worsening of any condition with devices that monitor and diagnose. Our goals are to cause damaged tissue to be regenerated, if possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, we are focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute hear
'/>"/>

SOURCE Bioheart, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Bioheart, Inc. Announces Additional Funding Support
2. United States FDA Clears the REGEN Trial to Test Biohearts Combination Gene and Stem Cell Therapy in Heart Failure Patients
3. Bioheart Strengthens Executive Team in Order to Accelerate Business Plan and Enhance Its Position in the Cardiovascular Stem Cell Therapy Industry
4. Bioheart Inc. to Participate in the 2009 World Stem Cell Summit on September 23rd
5. Bioheart Makes Breakthrough in Critical Limb Ischemia Therapy with Stem Cells Obtained from Fat Tissue
6. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
7. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
8. Par Pharmaceutical Reports Second Quarter 2008 Results
9. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
10. Pharmos Corporation Reports 2008 Second Quarter Results
11. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Over the last decade, the laboratory filtration market ... and increased acceptance of new filtration technologies in end ... are also catalyzing the growth of laboratory filtration market. ... grow at a strong CAGR during the forecast period ... million by 2019. The market is mainly driven by ...
(Date:9/30/2014)... 2014 CORD:USE Cord Blood Bank – ... has entered into an Equity and Exclusive Services Agreement ... series of patented technologies for the isolation of human ... Tianhe is performing Phase I/II clinical trials in ... using Tianhe,s Stem Cell Educator Therapy showing that ...
(Date:9/30/2014)...  KemPharm, Inc., a clinical-stage specialty pharmaceutical company ... new molecular entity (NME) prodrugs, announced today that ... issued U.S. Patent No. 8,816,083 to KemPharm for ... Derivatives and Heteroaryl Carboxylic Acid Conjugates of Hydromorphone, ... The patent, which extends through 2032, provides ...
(Date:9/30/2014)... 30, 2014 The overall research objective ... sequencing trends and use. Most researchers outsource NGS ... to increase within the next 12 months. Data ... for purchasing sequencing instruments. Disease-related research is the ... RNA-Seq continues to surge, with half of the ...
Breaking Biology Technology:Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 4Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 5CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2Global Next-generation Sequencing Trends 2
... LAFAYETTE, Ind. - The National Nuclear Security Administration has ... center at Purdue University,s Discovery Park to develop advanced ... Friday (March 7). , The center will focus on ... one of five new Centers of Excellence chosen by ...
... LLY ) today announced the termination of development ... partnership with Alkermes,Inc. The program has been in phase ... and type 2 diabetes. The company noted that this,decision ... Insulin trials,relating to the safety of the product, but ...
... CHICAGO, March 7 Advanced Life Sciences,Holdings, Inc. ... has received notice,from the Nasdaq Listing Qualifications Department ... the bid price for the Company,s,common stock has ... for,continued inclusion under Marketplace Rule 4310(c)(4) (the "Rule"). ...
Cached Biology Technology:Purdue leads center to simulate behavior of micro-electromechanical systems 2Purdue leads center to simulate behavior of micro-electromechanical systems 3Purdue leads center to simulate behavior of micro-electromechanical systems 4Lilly Announces Termination of AIR Insulin Program 2Lilly Announces Termination of AIR Insulin Program 3Lilly Announces Termination of AIR Insulin Program 4Advanced Life Sciences Receives Nasdaq Notification 2Advanced Life Sciences Receives Nasdaq Notification 3
(Date:9/30/2014)... Calif. The National Institutes of Health (NIH) ... today to develop an electrode array system that ... brain works through unprecedented resolution and scale. , ... to support President Obama,s BRAIN (Brain Research ... research effort to revolutionize our understanding of the ...
(Date:9/30/2014)... scientists and engineers, led by Clemson University associate ... million grant from the U.S. Department of Energy,s ... a direct positive impact on South Carolina in ... radioactive contaminants. , "Understanding the scientific and engineering ... aspects of nuclear technologies is imperative if South ...
(Date:9/30/2014)... Journal of Medicine reports positive results of a ... the subset of lung cancer marked by rearrangement of ... patients with advanced non-small cell lung cancer testing positive ... percent, with 3 complete responses and 33 partial responses. ... the disease to resume its growth after being slowed ...
Breaking Biology News(10 mins):NIH taps lab to develop sophisticated electrode array system to monitor brain act 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 3Researchers get $5.25 million to advance nuclear technologies in South Carolina 2NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2
... species in the Amazon will survive even grim scenarios ... extinction rates of up to 50 percent, predict Smithsonian ... the journal Proceedings of the National Academy of ... be as they weather the next several decades of ...
... Medical Center and at the National Institute of Environmental ... chromosomes can recombine to change genomes and spawn new ... of repeated sequences in the genomes of most higher ... many repeats," said Lucas Argueso, Ph.D., a research scholar ...
... When you make a new material on a nano scale ... team lead by a Biotechnology and Biological Sciences research Council ... major challenge faced by nanotechnology scientists. With new research ... from the University of Liverpool, The School of Pharmacy (University ...
Cached Biology News:Extinction most likely for rare trees in the Amazon rainforest 2Duke-NIEHS team shows how DNA repairs may reshape the genome 2Scientists overcome nanotech hurdle 2Scientists overcome nanotech hurdle 3
HOXC11 Antibody...
Rabbit polyclonal to Raf1 ( Abpromise for all tested applications). entrezGeneID: 5894 SwissProtID: P04049...
Sheep polyclonal to hCG beta core fragment ( Abpromise for all tested applications). Antigen: Full length native protein (purified) from human urine. Entrez GeneID: 1082 Swiss Protein ID...
Mouse monoclonal [SIT-01] to SIT ( Abpromise for all tested applications). entrezGeneID: 27240 SwissProtID: Q9Y3P8...
Biology Products: